PCI Pharma Services (PCI) has announced the expansion of its Clinical site at Rockford (IL, US). PCI is a full-service provider of specialist outsourced drug manufacturing, clinical trial services and commercial packaging to the global biopharmaceutical industry.
Construction of the expanded Clinical Services facility began on 12 November 2018. The site is one of two US-based PCI locations supporting investigational medicinal products, complementing facilities in the UK, Europe and Australia.
The facility expansion at the Rockford location will provide 30,000sqft of additional space in support of primary and secondary packaging and labelling operations for investigational medicinal products at the Clinical Services Center of Excellence, including a dedicated 2-8°C packaging suite for cold chain products.
The expanded building, which is expected to open for business in late 2019 following internal fit-out and a period of validation and licensing, will provide increased flexibility to meet customer needs.
Purpose-built for scalable primary and secondary packaging and labelling, the new packaging suites offer maximum flexibility, with the ability to operate on either a standalone or integrated basis across suites.
The build will feature a state-of-the-art 2-8°C packaging room for cold chain products. Additionally, the expansion will include a reception area and will double the current office space to meet staff growth plans, demonstrating PCI’s commitment to investment in a leading position to support clients’ global clinical trial supply needs.
Brian Keesee, Vice President and General Manager at PCI, said: “We are extremely excited to see the initial construction begin on our clinical facility expansion at the Rockford site. The expansion was a direct result of listening to the needs of our customers."
"PCI is involved with clinical trials that are being executed all around the world and the ability to react quickly is paramount to ensuring the success of a trial. We are also seeing more focus on specialised medicines with special handling requirements."
"Particularly with the market growth in biologics and biosimilars, the need for temperature-controlled therapies continues to increase. The new suites will allow us to provide faster turn around times and increased flexibility."
“PCI’s continued investment in infrastructure and staff allows our clients to realise a safe and secure supply chain, ensuring their life-saving treatments are delivered on time to patients around the world. The flexible and scalable suites will aid in continuing to deliver on our number one commitment to clients: to provide the industry’s leading customer experience.”
